<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ticagrelor: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ticagrelor: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ticagrelor: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="16785" href="/d/html/16785.html" rel="external">see "Ticagrelor: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F13159402"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal, bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Do not use ticagrelor in patients with active pathological bleeding or a history of intracranial hemorrhage.</p>
<p style="text-indent:-2em;margin-left:2em;">Do not start ticagrelor in patients undergoing urgent coronary artery bypass graft surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">If possible, manage bleeding without discontinuing ticagrelor. Stopping ticagrelor increases the risk of subsequent cardiovascular events.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Aspirin dose and ticagrelor effectiveness in patients with acute coronary syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Maintenance doses of aspirin &gt;100 mg daily reduce the effectiveness of ticagrelor and should be avoided.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13159403"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Brilinta</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871351"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Ticagrelor;</li>
<li>Brilinta;</li>
<li>M-Ticagrelor;</li>
<li>TARO-Ticagrelor</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F12911322"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiplatelet Agent;</li>
<li>
                        Antiplatelet Agent, Non-thienopyridine;</li>
<li>
                        P2Y12 Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F12911370"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Use with caution or avoid use in patients at increased risk for bradycardic events.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> In patients who require concomitant therapeutic anticoagulation, antiplatelet selection and/or duration of therapy may differ in order to balance risks for thrombosis and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267'])">Ref</a></span>). Concurrent aspirin maintenance dose should not exceed 100 mg/day.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ST-elevation myocardial infarction:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Percutaneous coronary intervention, primary:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Loading dose: Oral:</b> 180 mg once as early as possible after diagnosis in combination with aspirin and a parenteral anticoagulant; followed by maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Maintenance dose: Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>First 12 months after diagnosis:</i> 90 mg twice daily beginning ~12 hours after the initial loading dose in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>After 12 months from diagnosis:</i> Reduce maintenance dose to 60 mg twice daily in combination with aspirin; in selected patients with ongoing high ischemic risk, may continue 90 mg twice daily in combination with aspirin. Also see "Duration of Therapy" below (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25773268','lexi-content-ref-27438319','lexi-content-ref-26965534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25773268','lexi-content-ref-27438319','lexi-content-ref-26965534'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Post-fibrinolysis:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>If fibrinolysis is chosen for reperfusion, it is recommended to administer clopidogrel (instead of ticagrelor) in combination with the fibrinolytic, aspirin, and a parenteral anticoagulant as soon as possible after diagnosis; subsequently, in patients &lt;75 years of age, may transition from clopidogrel to ticagrelor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-34895950','lexi-content-ref-30898608','lexi-content-ref-29525822']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-34895950','lexi-content-ref-30898608','lexi-content-ref-29525822'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Loading dose: Oral: </b>180 mg once ≥12 hours after administration of fibrinolytic therapy (regardless of whether clopidogrel was co-administered at the time of diagnosis); followed by maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-30898608','lexi-content-ref-29525822']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-30898608','lexi-content-ref-29525822'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Maintenance dose: Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>First 12 months after diagnosis:</i> 90 mg twice daily beginning ~12 hours after the initial loading dose in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-30898608','lexi-content-ref-29525822','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-30898608','lexi-content-ref-29525822','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>After 12 months from diagnosis:</i> Reduce maintenance dose to 60 mg twice daily in combination with aspirin; in selected patients with ongoing high ischemic risk, may continue 90 mg twice daily in combination with aspirin. Also see "Duration of Therapy" below (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25773268','lexi-content-ref-27438319','lexi-content-ref-26965534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25773268','lexi-content-ref-27438319','lexi-content-ref-26965534'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>No reperfusion: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Loading dose: Oral: </b>180 mg once as early as possible after diagnosis in combination with aspirin and a parenteral anticoagulant; followed by maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Maintenance dose: Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>First 12 months after diagnosis:</i> 90 mg twice daily beginning ~12 hours after the initial loading dose in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>After 12 months from diagnosis:</i> Reduce maintenance dose to 60 mg twice daily in combination with aspirin; in selected patients with ongoing high ischemic risk, may continue 90 mg twice daily in combination with aspirin. Also see "Duration of Therapy" below (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25773268','lexi-content-ref-27438319','lexi-content-ref-26965534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25773268','lexi-content-ref-27438319','lexi-content-ref-26965534'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration of therapy:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Preferred approach: Continue ticagrelor plus aspirin (dual antiplatelet therapy [DAPT]) for ≥12 months unless major bleeding is a concern. For patients at high risk of bleeding or who experience overt bleeding, DAPT for 6 months may be reasonable. If there have been no major bleeding complications within initial 12 months, continuation of DAPT may be considered. Reevaluate the need for DAPT at regular intervals based on bleeding and thrombotic risks. When DAPT is complete, discontinue ticagrelor and continue aspirin indefinitely for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-25773268','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-25773268','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Alternative approach in select patients to minimize bleeding events: Ticagrelor in combination with aspirin (DAPT) should be continued for 1 to 3 months after PCI, then discontinue aspirin and continue ticagrelor monotherapy. When ticagrelor is discontinued, restart aspirin for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-32543684','lexi-content-ref-31556978','lexi-content-ref-32551860','lexi-content-ref-30166073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-32543684','lexi-content-ref-31556978','lexi-content-ref-32551860','lexi-content-ref-30166073'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Non-ST-elevation acute coronary syndromes:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>The following dosing recommendations are the same whether reperfusion with percutaneous coronary intervention (PCI) is planned or no reperfusion is planned.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Loading dose: Oral:</b> 180 mg once as early as possible after diagnosis in combination with aspirin and a parenteral anticoagulant; followed by maintenance dose. If coronary angiography is planned soon after diagnosis, it is reasonable to delay the initial loading dose until after coronary anatomy is known (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance dose: Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>First 12 months after diagnosis:</i> 90 mg twice daily beginning ~12 hours after the initial loading dose in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>After 12 months from diagnosis</i>: Reduce maintenance dose to 60 mg twice daily in combination with aspirin. In selected patients with ongoing high ischemic risk, may continue 90 mg twice daily in combination with aspirin. Also see “Duration of Therapy” below (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25773268','lexi-content-ref-27438319','lexi-content-ref-26965534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25773268','lexi-content-ref-27438319','lexi-content-ref-26965534'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration of therapy:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Preferred approach: Continue ticagrelor plus aspirin (DAPT) for ≥12 months unless major bleeding is a concern. For patients at high risk of bleeding or who experience overt bleeding, DAPT for 6 months may be reasonable. If there have been no major bleeding complications within initial 12 months, continuation of DAPT may be considered. Reevaluate the need for DAPT at regular intervals based on bleeding and thrombotic risks. When DAPT is complete, discontinue ticagrelor and continue aspirin indefinitely for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-25773268','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-25773268','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Alternative approach in select patients to minimize bleeding events: Ticagrelor in combination with aspirin (DAPT) should be continued for 1 to 3 months after PCI, then discontinue aspirin and continue ticagrelor monotherapy. When ticagrelor is discontinued, restart aspirin for secondary prevention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-32543684','lexi-content-ref-31556978','lexi-content-ref-32551860','lexi-content-ref-30166073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-31237645','lexi-content-ref-32543684','lexi-content-ref-31556978','lexi-content-ref-32551860','lexi-content-ref-30166073'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fedabdd1-fabe-4762-bba3-05f1c288f37c">Coronary artery disease and high risk for ischemic cardiovascular events, primary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coronary artery disease (stable) and high risk for ischemic cardiovascular events, primary prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Evaluate bleeding and thrombotic risks as well as patient preferences when considering dual antiplatelet therapy versus monotherapy with aspirin for primary prevention<b>. </b>Some experts recommend limiting use of dual antiplatelet therapy to patients with coronary artery disease and diabetes mellitus, at high risk for ischemic cardiovascular events, and at low risk for bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31475798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31475798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 60 mg twice daily in combination with aspirin; continue ticagrelor and aspirin indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31475798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31475798'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cb0dae1-5a7d-47d2-8676-f5848ae53584">Minor ischemic stroke or high-risk transient ischemic attack</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Minor ischemic stroke (based on National Institutes of Health Stroke Scale score) or high-risk transient ischemic attack (TIA; based on ABCD<sup>2</sup> score):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May consider short-term dual antiplatelet therapy (DAPT) with ticagrelor in combination with aspirin in patients with recent (≤24 hours) minor ischemic stroke or high risk TIA and ipsilateral &gt;30% stenosis of a major intracranial artery. Initiate antiplatelet therapy as soon as possible in the absence of contraindications. If an IV thrombolytic was administered, delay starting antiplatelet therapy for at least 24 hours, but administer as soon as possible thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34024117','lexi-content-ref-32668111','lexi-content-ref-Filho.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34024117','lexi-content-ref-32668111','lexi-content-ref-Filho.1'])">Ref</a></span>). Avoid DAPT in patients with hemorrhagic transformation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Filho.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Filho.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>: Initial: 180 mg once in combination with aspirin, followed by 90 mg twice daily in combination with aspirin for 21 to 30 days. After completion of DAPT, continue long-term single-agent antiplatelet therapy with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34024117','lexi-content-ref-32668111','lexi-content-ref-Filho.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34024117','lexi-content-ref-32668111','lexi-content-ref-Filho.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5a987cb-ccff-4ac0-a154-864ff35e02a8">Percutaneous coronary intervention for stable ischemic heart disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Percutaneous coronary intervention for stable ischemic heart disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose: Oral:</b> 180 mg once prior to percutaneous coronary intervention in combination with aspirin and a parenteral anticoagulant; followed by a maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31556978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31556978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance dose: Oral:</b> 90 mg twice daily beginning ~12 hours after the initial loading dose in combination with aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31556978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31556978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> Continue ticagrelor plus aspirin for 1 to 3 months; then discontinue aspirin and continue ticagrelor monotherapy for up to 1 to 2 years. When ticagrelor is discontinued, switch to aspirin for treatment of stable ischemic heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cutlip.2','lexi-content-ref-31556978','lexi-content-ref-30166073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cutlip.2','lexi-content-ref-31556978','lexi-content-ref-30166073'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Transitioning between P2Y<sub>12</sub> inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: This provides general guidance on transitioning between P2Y<sub>12</sub> inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transitioning from another P2Y<sub>12 </sub>inhibitor to ticagrelor:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Transitioning from clopidogrel:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">≤30 days after acute coronary syndrome (ACS) or PCI: Administer ticagrelor 180 mg loading dose once within 24 hours after the last dose of clopidogrel (irrespective of timing of previous clopidogrel dose), followed by 90 mg twice daily beginning 12 hours later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084738','lexi-content-ref-Cutlip.1','lexi-content-ref-Lincoff.1','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084738','lexi-content-ref-Cutlip.1','lexi-content-ref-Lincoff.1','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;30 days after ACS or PCI: Administer ticagrelor 90 mg twice daily beginning 24 hours after the last dose of clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084738','lexi-content-ref-25773268','lexi-content-ref-20194878']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084738','lexi-content-ref-25773268','lexi-content-ref-20194878'])">Ref</a></span>). <b>Note: </b>Some experts administer a ticagrelor 180 mg loading dose once within 24 hours after the last dose of clopidogrel (irrespective of timing of previous clopidogrel dose), followed by 90 mg twice daily beginning 12 hours later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cutlip.1','lexi-content-ref-Lincoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cutlip.1','lexi-content-ref-Lincoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Transitioning from prasugrel: </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">≤30 days after ACS or PCI: Administer ticagrelor 180 mg loading dose once within 24 hours after the last dose of prasugrel (irrespective of timing of previous prasugrel dose), followed by 90 mg twice daily beginning 12 hours later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084738','lexi-content-ref-Cutlip.1','lexi-content-ref-27013060','lexi-content-ref-Lincoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084738','lexi-content-ref-Cutlip.1','lexi-content-ref-27013060','lexi-content-ref-Lincoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;30 days after ACS or PCI: Administer ticagrelor 90 mg twice daily beginning 24 hours after the last dose of prasugrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084738','lexi-content-ref-27013060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084738','lexi-content-ref-27013060'])">Ref</a></span>). <b>Note: </b>Some experts administer a ticagrelor 180 mg loading dose once within 24 hours after the last dose of prasugrel (irrespective of timing of previous prasugrel dose), followed by 90 mg twice daily beginning 12 hours later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cutlip.1','lexi-content-ref-Lincoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cutlip.1','lexi-content-ref-Lincoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990105"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21960668','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21960668','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29850937','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29850937','lexi-content-ref-manu.1'])">Ref</a></span>). A retrospective analysis of dialysis patients who had undergone percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) showed no difference in cardiovascular end points or bleeding for ticagrelor compared to clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30746615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30746615'])">Ref</a></span>); however, patients with end-stage kidney disease (ESKD) are at increased risk for bleeding, with or without antiplatelet therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24318806','lexi-content-ref-30746615','lexi-content-ref-25476742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24318806','lexi-content-ref-30746615','lexi-content-ref-25476742'])">Ref</a></span>); monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). A retrospective analysis of dialysis patients who had undergone PCI for AMI showed no difference in cardiovascular end points or bleeding for ticagrelor compared to clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30746615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30746615'])">Ref</a></span>); however, patients with ESKD are at increased risk for bleeding, with or without antiplatelet therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24318806','lexi-content-ref-30746615','lexi-content-ref-25476742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24318806','lexi-content-ref-30746615','lexi-content-ref-25476742'])">Ref</a></span>); monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987394"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, undergoes hepatic metabolism; use caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Avoid use.</p></div>
<div class="block doe drugH1Div" id="F12911371"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56746766"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bleeding</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor may cause <b> hemorrhage, including major hemorrhage</b>. In the PLATO trial, ticagrelor was associated with an increased rate of non-procedure related bleeding, but there was no difference in the rate of overall major bleeding compared with clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19717846'])">Ref</a></span>). In the EUCLID trial, bleeding risk was also similar between patients who received ticagrelor versus patients who received clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29992857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29992857'])">Ref</a></span>). In the ISAR-REACT 5 trial, there was no difference in the rate of major bleeding between patients who received ticagrelor versus patients who received prasugrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31475799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31475799'])">Ref</a></span>). In the THATO trial, ticagrelor in combination with aspirin was associated with an increased risk of severe bleeding and intracranial hemorrhage compared to aspirin monotherapy in those with an acute ischemic stroke or transient ischemic attack (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32668111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32668111'])">Ref</a></span>). Reports of fatal or severe bleeding, including fatal and nonfatal intracranial bleeding, were rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29992857','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29992857','lexi-content-ref-19717846'])">Ref</a></span>). Bleeding should be suspected if the patient becomes hypotensive following recent coronary angiography, percutaneous coronary intervention, coronary artery bypass graft (CABG), or other surgical procedure, even in the absence of overt signs of bleeding. Studies suggest that platelet transfusions are ineffective in reversing the antiplatelet effect of ticagrelor, possibly due to reversible binding to the P2Y<sub>12</sub> receptor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29582544','lexi-content-ref-26050250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29582544','lexi-content-ref-26050250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; bleeding events occurred at all time points, up to 12 months of follow-up, with bleeding in some instances within 30 days of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31553203','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31553203','lexi-content-ref-19717846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Low body weight (≤65 kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33739127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33739127'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hemoglobin ≤12 g/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33739127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33739127'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic kidney disease (CrCl &lt;60 mL/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33739127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33739127'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Moderate to severe hepatic impairment</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other medications that increase bleeding risk (eg, anticoagulants, aspirin, nonsteroidal anti-inflammatory drugs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700620'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (≥80 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867508'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent trauma or surgery (eg, CABG)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent or recurrent GI bleeding</p>
<p style="text-indent:-2em;margin-left:6em;">• Active peptic ulcer disease</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bradyarrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ventricular pause and bradyarrhythmias, including <b>atrioventricular </b>(AV)<b> block</b>, have been reported with the use of ticagrelor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21545948','lexi-content-ref-30479952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21545948','lexi-content-ref-30479952'])">Ref</a></span>). In the PLATO trial, a non-statistically significant higher incidence of bradyarrhythmias was found, and statistical significance was confirmed in a substudy of patients enrolled in the PLATO trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21545948','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21545948','lexi-content-ref-19717846'])">Ref</a></span>). Bradyarrhythmias consisted primarily of asymptomatic and nocturnal ventricular pause originating from the sinoatrial node (SA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21545948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21545948'])">Ref</a></span>). These bradyarrhythmias have rarely been associated with syncope which are reversible upon discontinuation of ticagrelor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21545948','lexi-content-ref-30479952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21545948','lexi-content-ref-30479952'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not fully established; one potential mechanism includes direct effects on cardiac automaticity or conduction by P2Y<sub>12</sub> inhibition. Another potential mechanism includes inhibition of adenosine uptake by erythrocytes, increasing systemic adenosine concentrations, exacerbating vagal-mediated nocturnal bradycardia, and/or directly inhibiting SA node conduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1531622','lexi-content-ref-21545948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1531622','lexi-content-ref-21545948'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; ventricular pauses ≥3 seconds were noted more frequently with ticagrelor than with clopidogrel during the first week following hospitalization for an acute coronary syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21545948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21545948'])">Ref</a></span>). In some case studies, <b>bradycardia</b> occurred within hours after ticagrelor administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27057966','lexi-content-ref-26595794','lexi-content-ref-30479952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27057966','lexi-content-ref-26595794','lexi-content-ref-30479952'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of AV nodal blocking agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28560235']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28560235'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying conduction disorder (sick sinus syndrome, AV nodal block, left or right bundle branch block, bradycardia-related syncope not protected by a pacemaker) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28560235']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28560235'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Respiratory effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Respiratory effects, including <b>dyspnea</b> (most common) and <b>sleep apnea</b>, including <b>Cheyne-Stokes respiration</b>, have been reported with ticagrelor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25773268','lexi-content-ref-27602681','lexi-content-ref-32334703','lexi-content-ref-31482841','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25773268','lexi-content-ref-27602681','lexi-content-ref-32334703','lexi-content-ref-31482841','lexi-content-ref-19717846'])">Ref</a></span>). Multiple trials have reported an increased incidence of dyspnea in patients receiving ticagrelor compared to clopidogrel or aspirin alone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25773268','lexi-content-ref-32334703','lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25773268','lexi-content-ref-32334703','lexi-content-ref-19717846'])">Ref</a></span>). One study reported central sleep apnea hypopnea syndrome and obstructive sleep apnea hypopnea syndrome more frequently in patients taking ticagrelor; however, other studies have not found this association (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33550173','lexi-content-ref-32327085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33550173','lexi-content-ref-32327085'])">Ref</a></span>). Although not fatal, dyspnea and sleep apnea may not be well tolerated, warranting discontinuation. In most cases, dyspnea is self-limiting and resolves within 1 week of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19717846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19717846'])">Ref</a></span>). Sleep apnea also appears to resolve upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33550173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33550173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–­dose-related; inhibits sodium-independent equilibrative nucleoside transporter-1, increasing adenosine levels in plasma and affecting vagal fibers in the lungs, leading to dyspnea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33550173','lexi-content-ref-29794083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33550173','lexi-content-ref-29794083'])">Ref</a></span>). Additionally, ticagrelor may have CNS P2Y<sub>12</sub> receptor inhibitory effects, increasing chemo-sensitivity to hypercapnia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33550173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33550173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Dyspnea: Rapid; typically develops within the first 24 hours of therapy; however, may occur later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29601310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29601310'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Sleep apnea: Varied; sleep apnea events occurred from 7 days to up to 1 year following therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33550173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33550173'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29601310','lexi-content-ref-30283625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29601310','lexi-content-ref-30283625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;70 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29601310','lexi-content-ref-30283625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29601310','lexi-content-ref-30283625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic obstructive pulmonary disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30283625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30283625'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombotic thrombocytopenic purpura (TTP)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>thrombotic thrombocytopenic purpura</b> (TTP<b>)</b> associated with ticagrelor have been reported, and while rare, some have resulted in fatalities, particularly following rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28144007','lexi-content-ref-29952973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28144007','lexi-content-ref-29952973'])">Ref</a></span>). The overall evidence of ticagrelor-associated TTP is limited to case reports. Early signs of TTP may include neurologic changes (eg, headache, fatigue, hemiparesis/stroke) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28144007','lexi-content-ref-28959112','lexi-content-ref-29952973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28144007','lexi-content-ref-28959112','lexi-content-ref-29952973'])">Ref</a></span>). TTP is typically characterized by thrombocytopenia, hemolytic anemia, kidney or liver failure, and fever (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28144007','lexi-content-ref-29952973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28144007','lexi-content-ref-29952973'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Possibly immunologic; production of autoantibodies against ADAMTS-13, inducing microvascular thrombosis and other symptoms of TTP may play a major role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28144007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28144007'])">Ref</a></span>). In several cases, low ADAMTS-13 was found, supporting this mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Medamana.2021','lexi-content-ref-29952973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Medamana.2021','lexi-content-ref-29952973'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; patients presented from 2 weeks to 2 months following initiation of ticagrelor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28144007','lexi-content-ref-Medamana.2021','lexi-content-ref-28959112','lexi-content-ref-29952973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28144007','lexi-content-ref-Medamana.2021','lexi-content-ref-28959112','lexi-content-ref-29952973'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F12911329"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Respiratory: Dyspnea (14% to 21%)<span class="lexi-table-link-container"> (<a aria-label="Dyspnea table link" class="lexi-table-link" data-table-id="lexi-content-dyspnea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dyspnea')">table 1</a>)</span><span class="table-link" style="display:none;">Dyspnea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dyspnea" frame="border" id="lexi-content-dyspnea" rules="all">
<caption style="text-align:center;">
<b>Ticagrelor: Adverse Reaction: Dyspnea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ticagrelor)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Clopidogrel)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ticagrelor)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clopidogrel)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9,619</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9,235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9,186</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,958</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,996</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: ECG abnormality (ventricular pause: 2% to 6%)<span class="lexi-table-link-container"> (<a aria-label="ECG Abnormality table link" class="lexi-table-link" data-table-id="lexi-content-ecg-abnormality" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ecg-abnormality')">table 2</a>)</span><span class="table-link" style="display:none;">ECG Abnormality</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="ECG Abnormality" frame="border" id="lexi-content-ecg-abnormality" rules="all">
<caption style="text-align:center;">
<b>Ticagrelor: Adverse Reaction: ECG Abnormality</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ticagrelor)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Clopidogrel)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ventricular pauses; acute phase</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ventricular pauses; after 1 month</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (4%; major hemorrhage: 4%)<span class="lexi-table-link-container"> (<a aria-label="Major Hemorrhage table link" class="lexi-table-link" data-table-id="lexi-content-major-hemorrhage" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-major-hemorrhage')">table 3</a>)</span><span class="table-link" style="display:none;">Major Hemorrhage</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Major Hemorrhage" frame="border" id="lexi-content-major-hemorrhage" rules="all">
<caption style="text-align:center;">
<b>Ticagrelor: Adverse Reaction: Major Hemorrhage</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ticagrelor)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Clopidogrel)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ticagrelor)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clopidogrel)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9,235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9,186</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Noncoronary artery bypass graft surgery-related bleeding events</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Gout (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (4% to 7%; transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Increased uric acid</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block (Waldmann 2018), bradycardia (Waldmann 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombotic thrombocytopenic purpura (Wang 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Piranavan 2018; Seecheran 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cheyne-Stokes respiration (Giannoni 2016), sleep apnea (central) (Paboeuf 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Laboratory test abnormality (false negative platelet functional tests, including heparin-induced platelet aggregation [HIPA] assay)</p></div>
<div class="block coi drugH1Div" id="F12911326"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, angioedema) to ticagrelor or any component of the formulation; active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage); history of intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Moderate to severe hepatic impairment; concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir, atazanavir, nefazodone)</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F12911327"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperuricemia: Use with caution in patients with a history of hyperuricemia or gouty arthritis. Renal uptake and transport of uric acid are inhibited by ticagrelor and its active metabolite and the risk of hyperuricemia may be increased (Butler 2012a; Zhang 2015). However, reports of gout did not differ between treatment groups in the PLATO trial.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with platelet disorders, bleeding disorders, and/or at increased risk for bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heparin-induced thrombocytopenia: False-negative results may occur for platelet activation functional assays, which are used to diagnose heparin-induced thrombocytopenia. This may be due to ticagrelor inhibition of P2Y<sub>12 </sub>receptors on healthy donor platelets, which are used for the assay, reducing platelet activation and interfering with results.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate hepatic impairment (limited experience); avoid use in severe hepatic impairment (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Creatinine levels may rise during therapy (mechanism undetermined); monitor renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute ischemic stroke/transient ischemic attack patients: Use is not recommended in acute ischemic stroke or transient ischemic attack patients with an NIHSS score &gt;5 or patients receiving thrombolysis; not studied.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed who are on antiplatelet medications; risk of ongoing bleeding should be weighed with risk of thromboembolic events. In patients receiving dual antiplatelet therapy (aspirin plus P2Y<sub>12 </sub>receptor blocker [eg, clopidogrel, prasugrel, ticagrelor, ticlopidine]) or thienopyridine monotherapy, the thienopyridine should generally be resumed as soon as possible and at least within 7 days, taking into account control of bleeding and cardiovascular risk (aspirin should not be discontinued); however, dual antiplatelet therapy should not be discontinued in the 90 days post-acute coronary syndrome or 30 days post-coronary stenting (Strate 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: For elective coronary artery bypass graft (CABG) surgery, discontinue ticagrelor at least 3 days before surgery; when urgent CABG is necessary, discontinue ticagrelor for at least 24 hours prior to surgery (patient-specific situations should be discussed with a cardiologist, interventional cardiologist, and a cardiac surgeon) (ACC/AHA [Grines 2007]; ACC/AHA [Lawton 2022]). In patients undergoing noncardiac surgery, the risks and benefits of ticagrelor should be evaluated between the surgeon and the cardiology team. Elective noncardiac surgery should not be performed in patients in whom dual antiplatelet therapy (DAPT) will need to be discontinued perioperatively within 30 days following bare metal stent placement or within 3 months of drug-eluting stent placement. In patients undergoing urgent noncardiac surgery during the first 4 to 6 weeks after BMS or DES placement, continue DAPT. In patients undergoing noncardiac surgery that requires discontinuation of ticagrelor, hold for 3 to 5 days preoperatively, continue aspirin and restart ticagrelor as soon as possible (eg, ≤24 hours) after surgery based on bleeding and thrombotic risks (ACC/AHA [Fleisher 2014]; ACC/AHA [Lawton 2022]; ACC/AHA [Levine 2016]; ACCP [Douketis 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: For patients who undergo percutaneous coronary intervention with stenting, premature interruption of therapy may result in increased risk of myocardial infarction, stent thrombosis, stroke, or death. If therapy must be held temporarily (eg, bleeding, surgery), restart as soon as possible. Duration of therapy is determined by the type of stent placed (bare metal or drug eluting), whether an acute coronary syndrome event was ongoing at the time of placement, as well as risks for bleeding and thrombosis (ACC/AHA [Lawton 2022]).</p></div>
<div class="block foc drugH1Div" id="F13168279"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Brilinta: 60 mg, 90 mg</p></div>
<div class="block geq drugH1Div" id="F20452806"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322904"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Brilinta Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $9.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $9.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871352"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Brilinta: 60 mg, 90 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg, 90 mg</p></div>
<div class="block adm drugH1Div" id="F12911378"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer with or without food. Missed doses should be taken at their next regularly scheduled time. For patients unable to swallow whole, tablets may be crushed and mixed with water to create a suspension for oral or NG (CH8/Fr8 or greater according to the manufacturer) use. If suspension is administered orally, refill glass with water, stir and drink; if administered via NG tube, flush NG tube through with water after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737454','lexi-content-ref-Parodi.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737454','lexi-content-ref-Parodi.2015'])">Ref</a></span>). Administration of crushed tablets, while bioequivalent to administration of whole tablets, may result in increased concentrations of ticagrelor and the major active metabolite at earlier time points (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25500486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25500486'])">Ref</a></span>).</p></div>
<div class="block meg drugH1Div" id="F13135647"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F022433s034lbl.pdf%23page%3D35&amp;token=p2%2FpafpCKReP3mWRep2uao1zgLR%2FpZW3xNELwqWGE9fRLZkNRSgaBd233586GM1MNoRsrTlSrD661d1dE1B%2BrIyY0kGyfHIvdWFB%2FuIeCgdxuWQ8JfsgjHXVaG5YXYke&amp;TOPIC_ID=16784" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022433s034lbl.pdf#page=35</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F12911323"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome:</b> To reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. Ticagrelor also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Coronary artery disease (stable) and high risk for ischemic cardiovascular events, primary prevention: </b>To reduce the risk of first MI or stroke in patients with coronary artery disease at high risk for such events. <b>Note:</b> Efficacy was established in patients with type 2 diabetes mellitus (Steg 2019), but the manufacturer does not limit use to this setting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Minor ischemic stroke (based on National Institutes of Health Stroke Scale score) or high-risk transient ischemic attack (based on ABCD<sup>2</sup> score):</b> To reduce the risk of stroke in patients who meet these criteria.</p></div>
<div class="block off-label drugH1Div" id="F54947930"><span class="drugH1">Use: Off-Label: Adult</span><p>Percutaneous coronary intervention for stable ischemic heart disease</p></div>
<div class="block mst drugH1Div" id="F24937470"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Brilinta may be confused with Brintellix, Briviact.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Beers Criteria: Ticagrelor is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution, especially in patients 75 years and older due to increased risk of bleeding compared with clopidogrel; however, cardiovascular benefit in certain older adults may offset risk (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F12930100"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F12931836"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Agents with Antiplatelet Properties may enhance the antiplatelet effect of Abrocitinib.  Management: Do not use antiplatelet drugs with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated. This does not apply to low dose aspirin (81 mg/day or less).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: May enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in adult patients receiving daily aspirin doses greater than 100-150 mg daily. Management: Avoid daily aspirin doses greater than 100 mg in adults receiving ticagrelor.  Canadian recommendations are to avoid adult daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: Ticagrelor may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of Ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Ticagrelor may enhance the anticoagulant effect of Dabigatran Etexilate. Ticagrelor may increase the serum concentration of Dabigatran Etexilate.  Management: Carefully consider the anticipated risks and benefits of this combination. Increase monitoring bleeding if these agents are combined and consider avoiding the use of this combination in the presence of reduced renal function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diamorphine: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Diamorphine may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Ticagrelor may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: Ticagrelor may increase the serum concentration of Lomitapide.  Management: Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half with concurrent ticagrelor; the lomitapide dose may then be increased to a max adult dose of 30 mg/day (patients on lomitapide 5 mg/day may continue that dose).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: Ticagrelor may increase the serum concentration of Lovastatin.  Management: Limit lovastatin doses to 40 mg/day if coadministered with ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: Ticagrelor may increase the serum concentration of Red Yeast Rice.  Management: Avoid using doses of red yeast rice greater than the equivalent of lovastatin 40 mg/day with ticagrelor. Monitor for increased systemic effects of lovastatin in patients receiving concurrent ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Ticagrelor may enhance the myopathic (rhabdomyolysis) effect of Rosuvastatin. Ticagrelor may increase the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Ticagrelor may increase the serum concentration of Simvastatin.  Management: Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor. Monitor for increased systemic effects of simvastatin in patients receiving concurrent ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F12911324"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of ticagrelor in pregnancy is limited (Verbruggen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Due to lack of data, use in pregnancy is not recommended (ESC [Regitz-Zagrosek 2018]).</p></div>
<div class="block brc drugH1Div" id="F12911325"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ticagrelor is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F12911386"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of bleeding; hemoglobin and hematocrit periodically; sign/symptoms of bradycardia; renal function; uric acid levels (patients with gout or at risk of hyperuricemia); signs/symptoms of dyspnea.</p></div>
<div class="block pha drugH1Div" id="F12911349"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversibly and noncompetitively binds the adenosine diphosphate (ADP) P2Y<sub>12</sub> receptor on the platelet surface which prevents ADP-mediated activation of the GPIIb/IIIa receptor complex thereby reducing platelet aggregation. Due to the reversible antagonism of the P2Y<sub>12</sub> receptor, recovery of platelet function is likely to depend on serum concentrations of ticagrelor and its active metabolite.</p></div>
<div class="block phk drugH1Div" id="F12911351"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of inhibition of platelet aggregation (IPA): 180 mg loading dose: ~41% within 30 minutes (similar to clopidogrel 600 mg at 8 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Time to maximal IPA: 180 mg loading dose: IPA ~88% at 2 hours post administration</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of IPA: 180 mg loading dose: 87% to 89% maintained from 2 to 8 hours; 24 hours after the last maintenance dose, IPA is 58% (similar to maintenance dosing for clopidogrel)</p>
<p style="text-indent:-2em;margin-left:4em;">Time after discontinuation when IPA is 30%: ~56 hours; IPA 10%: ~110 hours (Gurbel 2009). Mean IPA observed with ticagrelor at 3 days post-discontinuation was comparable to that observed with clopidogrel at 5 days post discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 88 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99% (parent drug and active metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4/5 to active metabolite (AR-C124910XX)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~36% (range: 30% to 42%)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Parent drug: ~7 hours; active metabolite: ~9 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Whole tablets:</i> Parent drug: 1.5 hours (median; range: 1 to 4 hours); Active metabolite (AR-C124910XX): 2.5 hours (median; range: 1.5 to 5 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Crushed tablets:</i> Oral or nasogastric tube administration: Parent drug: ~1 hour (median; range: 1 to 4 hours); Active metabolite (AR-C124910XX): 2 hours (median; range: 1 to 8 hours). <b>Note:</b> Significantly higher concentrations of both ticagrelor and AR-C124910XX may appear at earlier time points (0.5 and 1 hour, respectively) when administered as crushed tablets (Teng 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (58%); urine (26%); actual amount of parent drug and active metabolite excreted in urine was &lt;1% of total dose administered</p></div>
<div class="block phksp drugH1Div" id="F51204228"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC and C<sub>max</sub> were 38% and 51% higher, respectively, in patients with end-stage renal disease on hemodialysis compared to patients with normal renal function following a single 90 mg dose of ticagrelor administered on a nondialysis day; similar exposure was observed when administered immediately prior to dialysis. Inhibition of platelet aggregation was independent of dialysis and similar to healthy adults with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Cigarette smoking: Mean clearance was increased by ~22% in smokers.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13276713"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Brilique | Ticazan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acora | Brilinta | Ticacard | Ticaflow | Ticalog | Tigel</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Coaly | Tiag</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Revagrel</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Tiare | Ticagrel | Vasogrelor</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Brilique | Lintaram | Thrombolinta</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Brilique</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Axcer | Brigrel | Brilinta | Tackel | Tiare | Ticabest | Ticabid | Ticacip | Ticaflo | Ticagat | Ticagold | Ticahenz | Ticaplat | Ticasave | Ticasave plus | Ticaspan | Ticastro | Ticatroy | Ticavic | Ticus | Tigemac | Tikacad | Torplat | Vasoglor | Xygrel</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Thincor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Corolor | Tiglor</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Austica | Boryung ticagrelor | Brelor | Brilcoron | Brilgrelor | Brilinta | Brilor | Britica | Btaon | Dongkoo ticagrelor | Glotica | Hutica | Inno.n ticagrelor | Samjin ticagrelor | Seoul ticagrelor | Tibrinta | Ticabrel | Ticabril | Ticada | Ticagen | Ticagle | Ticagrin | Ticaon | Ticarax | Tielinta | Tiglia | Tiglor | Tigrel | Tigrela | Tirinta | Trilinta | Unitica | Yooyoung tica</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Klotego</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Ticagrelor sandoz</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Supagrel</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Anplag | Bilinta | Grehil | Virata</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Brilique</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Brilique | Theraglor</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Agrilor | Brilinta | Camilla | Tilanta | Tixalor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Brilinta</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Clenosan</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Platetica | Topogis</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Brilinta | Tiare | Ticagrel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084738">
<a name="29084738"></a>Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y<sub>12</sub> receptor-inhibiting therapies. <i>Circulation</i>. 2017;136(20):1955‐1975. doi:10.1161/CIRCULATIONAHA.117.031164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/29084738/pubmed" id="29084738" target="_blank">29084738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27057966">
<a name="27057966"></a>Baker NC, Nadour W, Friehling M. Clinically significant ticagrelor induced conduction abnormalities following percutaneous coronary intervention. <i>Int J Cardiol</i>. 2016;214:21-22. doi:10.1016/j.ijcard.2016.03.143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/27057966/pubmed" id="27057966" target="_blank">27057966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1531622">
<a name="1531622"></a>Belloni FL, Wang J, Hintze TH. Adenosine causes bradycardia in pacing-induced cardiac failure. <i>Circulation</i>. 1992;85(3):1118-1124. doi:10.1161/01.cir.85.3.1118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/1531622/pubmed" id="1531622" target="_blank">1531622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29992857">
<a name="29992857"></a>Berger JS, Abramson BL, Lopes RD, et al. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. <i>Vasc Med</i>. 2018;23(6):523-530. doi:10.1177/1358863X18775594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/29992857/pubmed" id="29992857" target="_blank">29992857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29582544">
<a name="29582544"></a>Bertling A, Fender AC, Schüngel L, et al. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor. <i>J Thromb Haemost</i>. 2018;16(6):1089-1098. doi:10.1111/jth.14014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/29582544/pubmed" id="29582544" target="_blank">29582544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30898608">
<a name="30898608"></a>Berwanger O, Lopes RD, Moia DDF, et al. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis: TREAT trial. <i>J Am Coll Cardiol</i>. 2019;73(22):2819‐2828. doi:10.1016/j.jacc.2019.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/30898608/pubmed" id="30898608" target="_blank">30898608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29525822">
<a name="29525822"></a>Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a randomized clinical trial. <i>JAMA Cardiol</i>. 2018;3(5):391‐399. doi:10.1001/jamacardio.2018.0612<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/29525822/pubmed" id="29525822" target="_blank">29525822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25773268">
<a name="25773268"></a>Bonaca MP, Bhatt DL, Cohen M, et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. <i>N Engl J Med</i>. 2015;372(19):1791-800. doi:10.1056/NEJMoa1500857<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/25773268/pubmed" id="25773268" target="_blank">25773268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27438319">
<a name="27438319"></a>Bonaca MP, Bhatt DL, Oude Ophuis T, et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial. <i>JAMA Cardiol</i>. 2016;1(4):425‐432. doi:10.1001/jamacardio.2016.1017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/27438319/pubmed" id="27438319" target="_blank">27438319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brilinta.2011">
<a name="Brilinta.2011"></a>Brilinta—dosing in the PLATO trial [written communication]. Wilmington, DE: AstraZeneca; August 2, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brilinta.2021.08">
<a name="Brilinta.2021.08"></a>Brilinta (ticagrelor) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brilinta.2022.01">
<a name="Brilinta.2022.01"></a>Brilinta (ticagrelor) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22190065">
<a name="22190065"></a>Butler K, Teng R. Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2012a;91(2):264-271.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/22190065/pubmed" id="22190065" target="_blank">22190065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21960668">
<a name="21960668"></a>Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. <i>J Clin Pharmacol</i>. 2012b;52(9):1388-1398. doi:10.1177/0091270011415526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/21960668/pubmed" id="21960668" target="_blank">21960668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33739127">
<a name="33739127"></a>Cho JY, Lee SY, Yun KH, et al. Factors related to major bleeding after ticagrelor therapy: Results from the TICO trial. <i>J Am Heart Assoc</i>. 2021;10(7):e019630. doi:10.1161/JAHA.120.019630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/33739127/pubmed" id="33739127" target="_blank">33739127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23737454">
<a name="23737454"></a>Crean B, Finnie C, Crosby A. Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo. <i>Drugs R D</i>. 2013;13:153-157. doi:10.1007/s40268-013-0018-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/23737454/pubmed" id="23737454" target="_blank">23737454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cutlip.1">
<a name="Cutlip.1"></a>Cutlip D, Lincoff AM. Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cutlip.2">
<a name="Cutlip.2"></a>Cutlip D, Nicolau JC. Long-term antiplatelet therapy after coronary artery stenting in stable patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31700620">
<a name="31700620"></a>Dahal K, Mustafa U, Sharma SP, et al. Ischemic and bleeding outcomes of triple therapy in patients on chronic anticoagulation undergoing percutaneous coronary intervention: A meta-analysis of randomized trials. <i>JRSM Cardiovasc Dis</i>. 2019;8:2048004019885572. doi:10.1177/2048004019885572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/31700620/pubmed" id="31700620" target="_blank">31700620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28560235">
<a name="28560235"></a>De Maria E, Borghi A, Modonesi L, Cappelli S. Ticagrelor therapy and atrioventricular block: Do we need to worry? <i>World J Clin Cases</i>. 2017;5(5):178-182. doi:10.12998/wjcc.v5.i5.178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/28560235/pubmed" id="28560235" target="_blank">28560235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25164528">
<a name="25164528"></a>Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. <i>Pharmacotherapy</i>. 2014;34(10):1077-1090. doi:10.1002/phar.1477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/25164528/pubmed" id="25164528" target="_blank">25164528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28144007">
<a name="28144007"></a>Doğan A, Özdemir B, Bal H, Özdemir E, Kurtoğlu N. Ticagrelor-associated thrombotic thrombocytopenic purpura. <i>Anatol J Cardiol</i>. 2017;17(1):73-74. doi:10.14744/AnatolJCardiol.2017.7426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/28144007/pubmed" id="28144007" target="_blank">28144007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085962">
<a name="25085962"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi:10.1161/CIR.0000000000000105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/25085962/pubmed" id="25085962" target="_blank">25085962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27013060">
<a name="27013060"></a>Franchi F, Faz GT, Rollini F, et al. Pharmacodynamic effects of switching from prasugrel to ticagrelor: results of the prospective, randomized SWAP-3 Study. <i>JACC Cardiovasc Interv</i>. 2016;9(11):1089‐1098. doi:10.1016/j.jcin.2016.02.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/27013060/pubmed" id="27013060" target="_blank">27013060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27602681">
<a name="27602681"></a>Giannoni A, Emdin M, Passino C. Cheyne-Stokes respiration, Chemoreflex, and ticagrelor-related dyspnea. <i>N Engl J Med</i>. 2016;375(10):1004-1006. doi:10.1056/NEJMc1601662<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/27602681/pubmed" id="27602681" target="_blank">27602681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32334703">
<a name="32334703"></a>Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. <i>Lancet</i>. 2020;395(10233):1374-1381. doi:10.1016/S0140-6736(20)30325-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/32334703/pubmed" id="32334703" target="_blank">32334703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17224480">
<a name="17224480"></a>Grines CL, Bonow RO, Casey DE, et al. AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A Science Advisory from the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association with representation from The American College Of Physicians. <i>Circulation.</i> 2007;115(6):813-818. http://www.acc.org/qualityandscience/clinical/pdfs/Final_Dual_Antiplatelet_Statement_010507.pdf.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/17224480/pubmed" id="17224480" target="_blank">17224480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19923168">
<a name="19923168"></a>Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET Study. <i>Circulation</i>. 2009;120(25):2577‐2585. doi:10.1161/CIRCULATIONAHA.109.912550<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/19923168/pubmed" id="19923168" target="_blank">19923168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20194878">
<a name="20194878"></a>Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. <i>Circulation</i>. 2010;121(10):1188‐1199. doi:10.1161/CIRCULATIONAHA.109.919456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/20194878/pubmed" id="20194878" target="_blank">20194878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31237645">
<a name="31237645"></a>Hahn JY, Song YB, Oh JH, et al; SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. <i>JAMA</i>. 2019;321(24):2428-2437. doi:10.1001/jama.2019.8146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/31237645/pubmed" id="31237645" target="_blank">31237645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2011;124(25):e956 and <i>Circulation</i>. 2012;126(7):e105]. <i>Circulation</i>. 2011;124(23):2610-2642. doi:10.1161/CIR.0b013e31823b5fee<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24318806">
<a name="24318806"></a>Huang KW, Leu HB, Luo JC, et al. Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis. <i>Dig Dis Sci</i>. 2014;59(4):807-813. doi:10.1007/s10620-013-2973-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/24318806/pubmed" id="24318806" target="_blank">24318806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32668111">
<a name="32668111"></a>Johnston SC, Amarenco P, Denison H, et al; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. <i>N Engl J Med</i>. 2020;383(3):207-217. doi:10.1056/NEJMoa1916870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/32668111/pubmed" id="32668111" target="_blank">32668111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32543684">
<a name="32543684"></a>Kim BK, Hong SJ, Cho YH, et al; TICO Investigators. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. <i>JAMA</i>. 2020;323(23):2407-2416. doi:10.1001/jama.2020.7580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/32543684/pubmed" id="32543684" target="_blank">32543684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34024117">
<a name="34024117"></a>Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/34024117/pubmed" id="34024117" target="_blank">34024117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33250267">
<a name="33250267"></a>Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J<i> Am Coll Cardiol</i>. 2021;77(5):629-658. doi:10.1016/j.jacc.2020.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/33250267/pubmed" id="33250267" target="_blank">33250267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30746615">
<a name="30746615"></a>Lee CH, Tsai TH, Lin CJ, Hsueh SK, Chung WJ, Cheng CI. Efficacy and safety of ticagrelor compared with clopidogrel in patients with end-stage renal disease with acute myocardial infarction. <i>Am J Cardiovasc Drugs</i>. 2019;19(3):325-334. doi:10.1007/s40256-018-00318-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/30746615/pubmed" id="30746615" target="_blank">30746615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27036918">
<a name="27036918"></a>Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2016;68(10):1082‐1115. doi:10.1016/j.jacc.2016.03.513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/27036918/pubmed" id="27036918" target="_blank">27036918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lincoff.1">
<a name="Lincoff.1"></a>Lincoff AM, Cutlip D. Acute ST-elevation myocardial infarction: Antiplatelet therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed July 21, 2021. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29601310">
<a name="29601310"></a>Lombardi N, Lucenteforte E, Torrini M, et al. Ticagrelor-related late-onset dyspnea as cause of emergency department visit: a 3-year outpatient study. <i>J Cardiovasc Med (Hagerstown)</i>. 2018;19(6):284-289. doi:10.2459/JCM.0000000000000656<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/29601310/pubmed" id="29601310" target="_blank">29601310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26050250">
<a name="26050250"></a>Maillard J, Cartier Faessler V, Fontana P, Bonhomme F. Lack of effect of platelet transfusions and desmopressin on intracranial bleeding in a patient receiving ticagrelor. <i>A A Case Rep</i>. 2015;4(12):169-171. doi:10.1213/XAA.0000000000000156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/26050250/pubmed" id="26050250" target="_blank">26050250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Medamana.2021">
<a name="Medamana.2021"></a>Medamana JL, Laljee S, Kiefer N, Brejt S. Abstract 12399: Don't burst my blood: Ticagrelor induced thrombotic thrombocytopenic purpura. Circulation. 2021;144:A12399.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31556978">
<a name="31556978"></a>Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. <i>N Engl J Med</i>. 2019;381(21):2032-2042. doi:10.1056/NEJMoa1908419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/31556978/pubmed" id="31556978" target="_blank">31556978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33550173">
<a name="33550173"></a>Meurin P, Ben Driss A, Defrance C, et al. Central sleep apnea after acute coronary syndrome and association with ticagrelor use. <i>Sleep Med</i>. 2021;80:39-45. doi:10.1016/j.sleep.2021.01.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/33550173/pubmed" id="33550173" target="_blank">33550173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32551860">
<a name="32551860"></a>O'Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y<sub>12</sub> inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Circulation</i>. 2020;142(6):538-545. doi:10.1161/CIRCULATIONAHA.120.046251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/32551860/pubmed" id="32551860" target="_blank">32551860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Filho.1">
<a name="Filho.1"></a>Oliveira-Filho J, Mullen MT. Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794083">
<a name="29794083"></a>Ortega-Paz L, Brugaletta S, Ariotti S, et al; HI-TECH investigators. Adenosine and ticagrelor plasma levels in patients with and without ticagrelor-related dyspnea. <i>Circulation</i>. 2018;138(6):646-648. doi:10.1161/CIRCULATIONAHA.118.034489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/29794083/pubmed" id="29794083" target="_blank">29794083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26595794">
<a name="26595794"></a>Ozturk C, Unlu M, Yildirim AO, et al. The progressed atrioventricular block associated with ticagrelor therapy may not require permanent pacemaker after acute coronary syndrome; it may be reversible. <i>Int J Cardiol</i>. 2016;203:822-824. doi:10.1016/j.ijcard.2015.11.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/26595794/pubmed" id="26595794" target="_blank">26595794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31482841">
<a name="31482841"></a>Paboeuf C, Priou P, Meslier N, Roulaud F, Trzepizur W, Gagnadoux F. Ticagrelor-associated shift from obstructive to central sleep apnea: a case report. <i>J Clin Sleep Med</i>. 2019;15(8):1179-1182. doi:10.5664/jcsm.7818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/31482841/pubmed" id="31482841" target="_blank">31482841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31553203">
<a name="31553203"></a>Park DW, Kwon O, Jang JS, et al; TICAKOREA Investigators. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: A randomized clinical trial. <i>Circulation</i>. 2019;140(23):1865-1877. doi:10.1161/CIRCULATIONAHA.119.041766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/31553203/pubmed" id="31553203" target="_blank">31553203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Parodi.2015">
<a name="Parodi.2015"></a>Parodi G, Xanthopoulou I, Bellandi B, et al. Ticagrelor crushed tablets administration in STEMI patients. The MOJITO study. <i>J Am Coll Cardiol</i>. 2015;65(5):511-512.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891370">
<a name="30891370"></a>Piranavan P, Kaur NJ, Marmoush F, Burton A, Hannan J. Ticagrelor-induced angioedema after percutaneous coronary intervention in a patient with a history of ischemic stroke and low response to clopidogrel: A rare dilemma. <i>Cureus</i>. 2018;10(12):e3720. doi:10.7759/cureus.3720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/30891370/pubmed" id="30891370" target="_blank">30891370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30283625">
<a name="30283625"></a>Prosser AE, Dawson JL, Koo K, et al. Real-world incidence of patient-reported dyspnoea with ticagrelor. <i>Ther Adv Drug Saf</i>. 2018;9(10):577-584. doi:10.1177/2042098618788991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/30283625/pubmed" id="30283625" target="_blank">30283625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.<i> Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32327085">
<a name="32327085"></a>Sabatine MS, Hiatt WR, Goto S, et al. No significant relationship between ticagrelor and sleep apnea in large, randomized, blinded trials. <i>JACC Cardiovasc Interv</i>. 2020;13(8):1012-1014. doi:10.1016/j.jcin.2020.02.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/32327085/pubmed" id="32327085" target="_blank">32327085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31475799">
<a name="31475799"></a>Schüpke S, Neumann FJ, Menichelli M, et al; ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. <i>N Engl J Med</i>. 2019;381(16):1524-1534. doi:10.1056/NEJMoa1908973<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/31475799/pubmed" id="31475799" target="_blank">31475799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21545948">
<a name="21545948"></a>Scirica BM, Cannon CP, Emanuelsson H, et al; PLATO Investigators. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. <i>J Am Coll Cardiol</i>. 2011;57(19):1908-1916. doi:10.1016/j.jacc.2010.11.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/21545948/pubmed" id="21545948" target="_blank">21545948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29391955">
<a name="29391955"></a>Seecheran R, Seecheran V, Persad S, Lalla S, Seecheran NA. Ticagrelor-induced angioedema: A rare and unexpected phenomenon. <i>Case Rep Cardiol</i>. 2017;2017:7612713. doi:10.1155/2017/7612713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/29391955/pubmed" id="29391955" target="_blank">29391955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28959112">
<a name="28959112"></a>Siao WZ, Chuang WY, Su CH, Huang SF, Tu WK, Chan KC. A rare case of ticagrelor-induced profound isolated thrombocytopenia. <i>Acta Cardiol Sin</i>. 2017;33(5):556-558. doi:10.6515/acs20161021c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/28959112/pubmed" id="28959112" target="_blank">28959112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31475798">
<a name="31475798"></a>Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. <i>N Engl J Med</i>. 2019;381(14):1309-1320. doi:10.1056/NEJMoa1908077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/31475798/pubmed" id="31475798" target="_blank">31475798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26965534">
<a name="26965534"></a>Storey RF, Angiolillo DJ, Bonaca MP, et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. <i>J Am Coll Cardiol</i>. 2016;67(10):1145‐1154. doi:10.1016/j.jacc.2015.12.062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/26965534/pubmed" id="26965534" target="_blank">26965534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26925883">
<a name="26925883"></a>Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi:10.1038/ajg.2016.41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/26925883/pubmed" id="26925883" target="_blank">26925883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867508">
<a name="32867508"></a>Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: Insights from the SWEDEHEART registry. <i>Circulation</i>. 2020;142(18):1700-1708. doi:10.1161/CIRCULATIONAHA.120.050645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/32867508/pubmed" id="32867508" target="_blank">32867508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25476742">
<a name="25476742"></a>Tanios BY, Itani HS, Zimmerman DL. Clopidogrel use in end-stage kidney disease. <i>Semin Dial</i>. 2015;28(3):276-281. doi:10.1111/sdi.12338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/25476742/pubmed" id="25476742" target="_blank">25476742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25500486">
<a name="25500486"></a>Teng R, Carlson G, Hsia J. An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. <i>Int J Clin Pharmacol Ther</i>. 2015;53(2):182-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/25500486/pubmed" id="25500486" target="_blank">25500486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29850937">
<a name="29850937"></a>Teng R, Muldowney S, Zhao Y, Berg JK, Lu J, Khan ND. Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. <i>Eur J Clin Pharmacol</i>. 2018;74(9):1141-1148. doi:10.1007/s00228-018-2484-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/29850937/pubmed" id="29850937" target="_blank">29850937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30166073">
<a name="30166073"></a>Vranckx P, Valgimigli M, Jüni P, et al; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i>. 2018;392(10151):940-949. doi:10.1016/S0140-6736(18)31858-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/30166073/pubmed" id="30166073" target="_blank">30166073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26607190">
<a name="26607190"></a>Verbruggen M, Mannaerts D, Muys J, Jacquemyn Y. Use of ticagrelor in human pregnancy, the first experience. <i>BMJ Case Rep</i>. 2015;2015:pii: bcr2015212217. doi:10.1136/bcr-2015-212217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/26607190/pubmed" id="26607190" target="_blank">26607190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30479952">
<a name="30479952"></a>Waldmann V, Laredo M, Nigam A, Khairy P. Cyclical sinus bradycardia and atrioventricular block induced by ticagrelor. <i>HeartRhythm Case Rep</i>. 2018;4(11):527-529. doi:10.1016/j.hrcr.2018.07.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/30479952/pubmed" id="30479952" target="_blank">30479952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19717846">
<a name="19717846"></a>Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med.</i> 2009;361(11):1045-1057. doi:10.1056/NEJMoa0904327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/19717846/pubmed" id="19717846" target="_blank">19717846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29952973">
<a name="29952973"></a>Wang X, Zhang S, Li L, et al. Ticagrelor-induced thrombotic thrombocytopenic purpura: a case report and review of the literature. <i>Medicine (Baltimore)</i>. 2018;97(26):e11206. doi:10.1097/MD.0000000000011206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/29952973/pubmed" id="29952973" target="_blank">29952973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25981572">
<a name="25981572"></a>Zhang N, Zhang Z, Yang Y, Xu Y, Li G, Liu T. Ticagrelor-related gout: an underestimated side effect. <i>Int J Cardiol</i>. 2015;192:11-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ticagrelor-drug-information/abstract-text/25981572/pubmed" id="25981572" target="_blank">25981572</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16784 Version 301.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
